Skip to main content

Ovarian Cancer

The approval of 3 PARP inhibitors has made it feasible to personalize therapy for patients with ovarian cancer based on their mutation status as well as other factors, including the treatment setting. Read More ›

The phase 3 PRIMA clinical trial demonstrated that time to first subsequent therapy was 6.6 months longer in the niraparib arm versus the placebo arm, an advantage that was maintained regardless of homologous recombination deficiency status, and the risk for second disease progression was also numerically lower in niraparib-treated patients. Read More ›

Improvement in progression-free survival observed in the PRIMA clinical trial results in FDA approval of an additional indication for niraparib as first-line maintenance treatment of all patients with advanced ovarian cancer whose disease has had a complete or partial response to first-line platinum-based chemotherapy. Read More ›

According to data from the National Cancer Institute, approximately 1.2% of women in the United States will be diagnosed with ovarian cancer at some point in their lifetime. It is estimated that more than 20,000 women will be diagnosed with ovarian cancer in 2020, and nearly 14,000 women will die from the disease in the same year. Most deaths will occur in women aged >55 years. Read More ›

In this exclusive interview, Melissa Paige, Chief Executive Officer and Founder, Paige Consulting, LLC, Charlottesville, VA, and Infusion/Oncology Patient Access Principal Coordinator at a large academic center, shares her experience in helping patients with cancer obtain access to oral and infused therapies. Read More ›

Remote patient monitoring, in which digital technologies are used to detect changes in vital signs or symptoms, may offer a convenient way to signal the need for a change in management, thereby potentially improving outcomes. Read More ›

When it comes to purchasing medical practice management software, information technology experts recommend certain features, including comprehensive appointment scheduling with automated appointment reminders, an online patient portal with secure messaging, and the ability to integrate with a practice’s electronic health record system. Read More ›

Although many individuals with cancer are offered access to patient portals, only two-thirds take advantage of this service when it is offered. Recent data showed that individuals with newly diagnosed cancer viewed their own electronic health record more frequently than cancer survivors or individuals who did not have cancer. Additional studies are warranted to determine which factors influence patient portal use so that effective interventions can be developed to increase the use of this valuable technology. Read More ›

In this exclusive interview, Melissa Paige, Chief Executive Officer and Founder, Paige Consulting, LLC, Charlottesville, VA, and Infusion/Oncology Patient Access Principal Coordinator at a large academic center, shares her experience in helping patients with cancer obtain access to oral and infused therapies. Read More ›

Medically integrated dispensing models enhance oral oncology drug education and improve compliance and patient monitoring. Read More ›

Page 10 of 13